Pectoral Block in Breast Reduction for Pain Control

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorCarilion Clinic

About this trial

A reduction mammoplasty is a commonly performed procedure for patients with symptomatic macromastia. The procedure involves removing breast parenchyma for an overall reduction in breast size and to alleviate patient symptoms, such as back/neck pain, rashes in the inframammary fold, and bra strap indentation. It is well documented in the literature that this procedure has a statistically significant reduction in patient symptoms. Postoperatively, it has been within the norm to prescribe narcotics in order to alleviate post-procedural pain. Recently, however, the research realm has advocated a non-narcotic multimodal pain control (MMPC) approach to minimize narcotic usage. Narcotic use is associated with increased costs in the healthcare system due to reported heightened pain scores for extended duration, constipation, nausea, vomiting, opiate dependence among other factors associated with increased morbidity.

The goal of this study is to determine if PECs II (pectoral block type II) block alone is non-inferior to the standard multimodal pain control with narcotics for postoperative pain reduction in breast reduction.

Eligibility criteria

Qualifiers

Undergoing breast reduction surgery

Women older than age 18 and under age 75

Stable breast size for at least 1 year

Patient has evidence of severe breast hypertrophy that is documented by frontal and side profile photographs

Disqualifiers

History of chronic pain controlled with prescribed narcotics

English as non-primary language

No access to email or internet

Positive pre-surgery pregnancy test

Trial design

Treatments tested in this trial

  • Pectoral II Nerve Block
  • Post Operative Pain Relievers

Treatment groups

80 Participants
are divided into 2 treatment groups

Sponsors and collaborators